This page contains exclusive content for the member of the following sections: TTS. Log in to view.
Presenter: Ayesha, Haroon, ,
Authors: Haroon A., Singer L., Hwang D., Binnie M., Chaparro C., Chow C., DePerrot M., Pierre A., Waddell T., Yasufuku K., Azad S., Keshavjee S., Tinckam K.
ASSAYS TO PREDICT ALLOGRAFT REJECTION
A. Haroon1, L. Singer2, D.M. Hwang2, M. Binnie2, C. Chaparro2, C. Chow2, M. Deperrot2, A. Pierre2, T.K. Waddell3, K. Yasufuku2, S. Azad2, S. Keshavjee2, K. Tinckam4
1, University of TOronto, Toronto/CANADA, 2, University of Toronto, Toronto/CANADA, 3Thoracic Surgery, Toronto General Research Institute, Toronto/ON/CANADA, 4Hla Laboratory - Dept Of Laboratory Medicine, University Health Network, Toronto/CANADA
Body: Introduction: Both pre-and post transplant HLA antibodies (HLAAb) in isolation have been correlated with bronchiolitis obliterans syndrome (BOS) and graft failure in lung transplant, but the temporal relationship of post transplant HLAAb to clinically relevant outcomes is not well described. Methods: We conducted a retrospective review of 98 consecutive lung transplant from 11/06 to 12/07 with 3 month survival, who had protocol post transplant HLAAb testing q3mo for one year (solid phase, Luminex ™ platform).We examined the relationship of HLAAb development and presence to acute rejection (AR), diffuse alveolar damage (DAD), infections, radiographic findings, 6-minute walk, and pulmonary function tests at 3,6,9,12, and 18 months post transplant. C4d staining was not routinely performed in this cohort’s biopsies. Patients were divided into 3 groups for comparison: no HLAAb pre- or post-transplant (NoAb n=58), sensitized with HLAAb pre-tx (PreTxAb, n=18),and post-transplant de novo HLAAb (DNAb, n=22). The PreTxAb group received our standard high-risk protocol of perioperative plasma exchange, IVIg and MMF. Routine immunosuppression with CsA, azathioprine and prednisone was used for the remaining patients. Where appropriate, categorical variables were compared with Chi-squared or Fisher’s exact test, and continuous variables were compared using T-test, ANOVA, Kruskal-Wallis or Rank-sum tests. Results: Of 22 DNAb, 18 developed Ab at 3-6 months and 4 at 9-12 months. 18 month survival between the three groups was not statistically different (NoAb 86.2%; PreTxAb 94.4%, DNAb 77.2%, p=NS log-rank) Immunosuppression therapy was comparable between NoAb and DNAb groups. There was no association between de novo HLAAb or pre-transplant HLAAb and AR, DAD, infection, 6 minute walk, or XR findings at any timepoint. Early de novo HLAAb, and to a lesser extent pre-transplant HLAAb, were associated with decreased FEV1 at 18 months post-transplant to <80% of best FEV1 achieved (BOS-1). (Table) After adjusting for AR and CMV infection in the first year, early DNAb remained a significant predictor of BOS at 18 months post-transplant (OR 7.68:2.28-25.8).
Table. Impact of PostTx HLAAb on FEV1 Over Time | ||||
NoAb | DNAb | PreTxAb | p | |
BOS-1 9m (% of recipients) (n=87 available) | 18.0 (9/50) | 25.0 (5/20) | 23.0 (4/17) | 0.71 |
BOS-1 12m (% of recipients) (n=83 available) | 14.0 (7/50) | 23.5 (4/17) | 18.7 (3/16) | 0.65 |
BOS-1 18m (% of recipients) (n=81 available) | 18.6 (9/48) | 70.6 (12/17) | 37.5 (6/16) | <0.001 |
% Best FEV1 9m (med:IQR) | 93: 86-97% | 88: 80-96% | 94: 81-98% | 0.57 |
% Best FEV1 12m (med:IQR) | 96: 88-100% | 92:82-96% | 95 :84-99% | 0.24 |
% Best FEV1 18m (med:IQR) | 97: 86-100% | 73: 65-87% | 92:65-97% | 0.0003 |
Disclosure: All authors have declared no conflicts of interest.
By viewing the material on this site you understand and accept that:
The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada